SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paradigm Genetics -- PDGM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (95)1/21/2006 11:50:28 AM
From: Mike McFarland  Read Replies (2) of 101
 
CLDA "reorganizing into two operating divisions to be known
as Clinical Data Molecular and Vital Diagnostics. The
Clinical Data Molecular division will consolidate the
operations of Genaissance Pharmaceuticals, Inc., Lark
Technologies, Inc. and Icoria, Inc., all of which were
acquired by the Company during 2005. The Vital Diagnostics
division will consolidate the operations of Clinical Data
Sales and Service, Inc., Vital Scientific NV, Vital
Diagnostics Pty. Ltd., and Electa Lab s.r.l., the
Company’s previously owned subsidiaries in the small volume
clinical diagnostics market.

clda.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext